Lantus Insulin More Effective in Achieving Long Term Blood Sugar Control in Type 2 Diabetes Patients

Shares

New results presented by Sanofi at European Association for the Study of Diabetes (EASD) 48th Annual Meeting showed treatment with Lantus (insulin glargine) was approximately 3 times more likely (p<0.001) to achieve and maintain target glycemic levels, defined as HbA1C < 6.5% in this analysis, vs. standard care in individuals with pre-diabetes or early type 2 diabetes at high cardiovascular (CV) risk.
The data from the ORIGIN (Outcome Reduction with Initial Glargine INtervention) trial showed that insulin glargine (Lantus) use was an independent predictor of maintaining mean yearly HbA1c < 6.5% target over 5 years, vs. standard care. Similarly, a lower HbA1c baseline level was also found to predict reaching the same target.

ORIGIN was a six-year randomized clinical trial designed to assess the effects of treatment with insulin glargine vs. standard care on CV outcomes and involved over 12,500 participants worldwide with pre-diabetes (impaired fasting glycemia or impaired glucose tolerance) or early type 2 diabetes (treated at most with one oral anti-diabetic) and high CV risk. Key results reported earlier this year at the American Diabetes Association Congress (June 2012) showed insulin glargine had a neutral effect on CV outcomes and significantly reduced progression from pre-diabetes to diabetes (secondary outcome) by 28% (p=0.006).

This analysis shows that insulin glargine generally brought glycemic control to HbA1c <6.5%, a commonly sought target, and sustained it over 5 years. Further study of the ORIGIN data is likely to provide further insights regarding the medical benefits or risks of this approach to treatment,” stated Professor Matthew Riddle M.D., Oregon Health and Science University, USA, lead author of this ORIGIN sub-analysis.

These new findings showed that insulin glargine was more effective than standard care at maintaining glycemic control in all subgroups assessed, including age, alcohol consumption, depression, baseline HbA1c, urine albumin:creatinine ratio (ACR), diabetes and particularly in individuals with abdominal obesity (p=0.011) and greater grip strength (p<0.001).

Leave a Reply

avatar
3000
  Subscribe  
Notify of
Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.